Grant

An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsored by Flamingo Therapeutics (Belgium)

Active

$275K Funding

2 People

External

Related Topics

immunotherapy, clinical trial, head and neck cancer, combination therapy, genetic therapy

People

Ricklie Julian
Principal Investigator (PI)
Medicine﹒Assistant Professor, Medicine - (Clinical Scholar Track)
Linda Garland
Co-Investigator (COI)
Medicine﹒Professor